Selected article for: "pathway signaling and potential target"
Author: Maximilian F Konig; Mike Powell; Verena Staedtke; Ren-Yuan Bai; David L Thomas; Nicole Fischer; Sakibul Huq; Adham M Khalafallah; Allison Koenecke; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Joshua T Vogelstein; Susan Athey; Shibin Zhou; Chetan Bettegowda
Title: Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome
  • Document date: 2020_4_8
    • ID: 0lwmzjxz_2
    Snippet: One potential target is the IL-6 signaling pathway. IL-6 levels diverge profoundly between survivors and non-survivors in the third week after symptom onset and are predictors of COVID-19 severity and in-hospital mortality (1, 6, 9) . Tocilizumab, a monoclonal antibody targeting the IL-6 receptor, is currently being investigated for the treatment of patients with COVID-19-CSS (10) . Pending data from randomized controlled trials, retrospective da.....
    Document: One potential target is the IL-6 signaling pathway. IL-6 levels diverge profoundly between survivors and non-survivors in the third week after symptom onset and are predictors of COVID-19 severity and in-hospital mortality (1, 6, 9) . Tocilizumab, a monoclonal antibody targeting the IL-6 receptor, is currently being investigated for the treatment of patients with COVID-19-CSS (10) . Pending data from randomized controlled trials, retrospective data from 21 patients with severe or critical COVID-19 treated with tocilizumab suggests that inhibition of the IL-6 signaling axis is highly effective (11) . However, given the cost, immunosuppression, and potential adverse reactions of tocilizumab, this strategy will likely be restricted to select patients in developed countries.

    Search related documents:
    Co phrase search for related documents
    • adverse reaction and hospital mortality: 1, 2
    • adverse reaction and monoclonal antibody: 1, 2
    • adverse reaction and patient treatment: 1, 2, 3, 4, 5, 6, 7
    • adverse reaction and randomized control trial: 1
    • adverse reaction and receptor target: 1
    • adverse reaction and signaling pathway: 1, 2
    • adverse reaction and symptom onset: 1, 2, 3, 4
    • axis signaling and monoclonal antibody: 1
    • axis signaling and receptor target: 1
    • axis signaling and signaling pathway: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • control trial and hospital mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • control trial and monoclonal antibody: 1, 2
    • control trial and patient treatment: 1, 2, 3, 4, 5, 6, 7
    • control trial and potential target: 1
    • control trial and randomized control trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • control trial and symptom onset: 1, 2, 3, 4
    • develop country and hospital mortality: 1